SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SMS Pharmaceuticals trades higher on the BSE

06 Jul 2012 Evaluate

SMS Pharmaceuticals is currently trading at Rs. 156.10, up by 1.60 points or 1.04% from its previous closing of Rs. 154.50 on the BSE.

The scrip opened at Rs. 159.50 and has touched a high and low of Rs. 159.50 and Rs. 156.10 respectively.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 200.00 on 07-Jul-2011 and a 52 week low of Rs. 128.05 on 08-Jun-2012.

Last one week high and low of the scrip stood at Rs. 160.00 and Rs. 146.00 respectively. The current market cap of the company is Rs. 159.74 crore.

The promoters holding in the company stood at 54.02% while Institutions and Non-Institutions held 1.12% and 44.86% respectively.

SMS Pharmaceuticals has received revised rating from credit rating agency, CARE. The rating agency has revised BBB+ rating from A- earlier for Rs 171 crore long term bank facilities of the company. The rating agency has also revised the company’s short term bank facilities worth Rs 47.56 crore to A3 from A2.

The company has received the said rating due to deterioration in sales and profitability margins during FY12 coupled with stoppage in receipt of regulatory approvals for its new units.

SMS Pharmaceuticals is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and its intermediates. The company has six manufacturing facilities and two R&D facilities located in Andhra Pradesh.

SMS Pharmaceuticals Share Price

396.55 -19.20 (-4.62%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×